---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-154016"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:27:02.291304+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026

## Summary
- IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.
- ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.
- Primary endpoint: mean percentage change from baseline in EASI score at Week 20.
- Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.
- Dose-finding study designed to guide optimal dosing for future Phase 3 trials.

## SEC filing metadata
- accession: 0001193125-25-154016
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/0001193125-25-154016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/d917926d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-154016
- JSON: https://secwatch.observer/filing/0001193125-25-154016.json
- Plain text: https://secwatch.observer/filing/0001193125-25-154016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.